PubMed:32178765 / 2109-2545 JSONTXT

{"target":"https://pubannotation.org/docs/sourcedb/PubMed/sourceid/32178765","sourcedb":"PubMed","sourceid":"32178765","source_url":"https://www.ncbi.nlm.nih.gov/pubmed/32178765","text":"The primary endpoint was met: ACR20 at week 24 was achieved by significantly greater proportions of patients in the guselkumab every 4 weeks group (76 [59%] of 128 [95% CI 50-68]) and every 8 weeks group (66 [52%] of 127 [43-61]) than in the placebo group (28 [22%] of 126 [15-30]), with percentage differences versus placebo of 37% (95% CI 26-48) for the every 4 weeks group and 30% (19-41) for the every 8 weeks group (both p\u003c0·0001).","tracks":[{"project":"Inflammaging","denotations":[{"id":"T16","span":{"begin":0,"end":436},"obj":"Sentence"},{"id":"T16","span":{"begin":0,"end":436},"obj":"Sentence"}],"attributes":[{"subj":"T16","pred":"source","obj":"Inflammaging"},{"subj":"T16","pred":"source","obj":"Inflammaging"}]},{"project":"yaoziqian_800_3","denotations":[{"id":"T14","span":{"begin":116,"end":126},"obj":"CI"},{"id":"T15","span":{"begin":242,"end":249},"obj":"CI"},{"id":"T16","span":{"begin":318,"end":325},"obj":"CI"}],"attributes":[{"subj":"T14","pred":"source","obj":"yaoziqian_800_3"},{"subj":"T15","pred":"source","obj":"yaoziqian_800_3"},{"subj":"T16","pred":"source","obj":"yaoziqian_800_3"}]},{"project":"Zierdiyeerkenaili_800_3","denotations":[{"id":"T14","span":{"begin":116,"end":126},"obj":"CI"},{"id":"T22","span":{"begin":242,"end":249},"obj":"CI"},{"id":"T23","span":{"begin":318,"end":325},"obj":"CI"}],"attributes":[{"subj":"T14","pred":"source","obj":"Zierdiyeerkenaili_800_3"},{"subj":"T22","pred":"source","obj":"Zierdiyeerkenaili_800_3"},{"subj":"T23","pred":"source","obj":"Zierdiyeerkenaili_800_3"}]}],"config":{"attribute types":[{"pred":"source","value type":"selection","values":[{"id":"Inflammaging","color":"#ec93c4","default":true},{"id":"yaoziqian_800_3","color":"#93deec"},{"id":"Zierdiyeerkenaili_800_3","color":"#ece093"}]}]}}